Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Gc Genome Corporation currently oversees 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This action is assigned to a distinct examiner and is being reviewed in a single art unit. The company's active prosecution is currently limited to this single administrative channel. This focus allows the applicant to dedicate their efforts to the specific requirements of one examination team.
KRIANGCHAIVECH, KETTIP is the busiest examiner for this portfolio, with 1 pending office action currently active. This accounts for the 1 pending office action total for the company. The outcome of this biotechnology patent application depends on the individual review of this examiner. Practitioners should analyze the examiner's history in the Biotechnology & Pharmaceuticals area to anticipate potential rejections and prepare effective responses.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KRIANGCHAIVECH, KETTIP | 1 | 19.0% | +28.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17780813 | ARTIFICIAL INTELLIGENCE-BASED CHROMOSOMAL ABNORMALITY DETECTION METHOD | KRIANGCHAIVECH, KETTIP | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17780813 | ARTIFICIAL INTELLIGENCE-BASED CHROMOSOMAL ABNORMALITY DETECTION METHOD | KRIANGCHAIVECH, KETTIP | — |
| Art Unit | Apps |
|---|---|
| 1686 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17780813 | ARTIFICIAL INTELLIGENCE-BASED CHROMOSOMAL ABNORMALITY DETECTION METHOD | KRIANGCHAIVECH, KETTIP | 1686 | §101Other | Final Rejection | — | Pending | May 27, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGc Genome Corporation has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Kettip Kriangchaivech has the most, with 1 of Gc Genome Corporation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
